| First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway M Hagel, C Miduturu, M Sheets, N Rubin, W Weng, N Stransky, N Bifulco, ... Cancer discovery 5 (4), 424-437, 2015 | 329 | 2015 |
| ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii TF Durand-Réville, S Guler, J Comita-Prevoir, B Chen, N Bifulco, H Huynh, ... Nature microbiology 2 (9), 1-10, 2017 | 252 | 2017 |
| Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors W Kazmierski, N Bifulco, H Yang, L Boone, F DeAnda, C Watson, ... Bioorganic & medicinal chemistry 11 (13), 2663-2676, 2003 | 156 | 2003 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent 8,802,697, 2014 | 141 | 2014 |
| Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma MA Hatlen, O Schmidt-Kittler, CA Sherwin, E Rozsahegyi, N Rubin, ... Cancer Discovery 9 (12), 1686-1695, 2019 | 97 | 2019 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent 9,126,951, 2015 | 90 | 2015 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, LV DiPietro, CV Miduturu US Patent 9,695,165, 2017 | 89 | 2017 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, LV DiPietro, BL Hodous, CV Miduturu US Patent 9,434,700, 2016 | 49 | 2016 |
| CCR5 antagonists as therapeutic agents WM Kazmierski, CJ Aquino, N Bifulco, EE Boros, BA Chauder, PY Chong, ... US Patent 7,645,771, 2010 | 49 | 2010 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent 9,340,514, 2016 | 44 | 2016 |
| First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015; 5: 424–437. doi … M Hagel, C Miduturu, M Sheets, N Rubin, W Weng, N Stransky, N Bifulco, ... Oncogene 19, 5636-42, 2000 | 40 | 2000 |
| Compounds and compositions useful for treating disorders related to NTRK SM Wenglowsky, CV Miduturu, N Bifulco, JL Kim US Patent 10,370,379, 2019 | 35 | 2019 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, LV DiPietro, BL Hodous, CV Miduturu US Patent 10,221,154, 2019 | 35 | 2019 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, N Brooijmans, BL Hodous, JL Kim, CV Miduturu US Patent App. 15/097,995, 2017 | 35 | 2017 |
| Compounds and compositions useful for treating disorders related to NTRK SM Wenglowsky, N Brooijmans, CV Miduturu, N Bifulco US Patent 10,017,512, 2018 | 33 | 2018 |
| Inhibitors of the fibroblast growth factor receptor N Bifulco, LV DiPietro, CV Miduturu US Patent 10,000,490, 2018 | 32 | 2018 |
| ETX2514 is a broad-spectrum betalactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2: 17104 TF Durand-Réville, S Guler, J Comita-Prevoir, B Chen, N Bifulco, H Huynh, ... | 32 | 2017 |
| The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: Hydroxyindole derivatives KL Milkiewicz, TH Marsilje, RP Woodworth Jr, N Bifulco Jr, MJ Hangauer, ... Bioorganic & medicinal chemistry letters 10 (5), 483-486, 2000 | 28 | 2000 |
| Substituted indanylacetic acids as PPAR-α–γ activators DB Lowe, N Bifulco, WH Bullock, T Claus, P Coish, M Dai, FED Cruz, ... Bioorganic & medicinal chemistry letters 16 (2), 297-301, 2006 | 15 | 2006 |
| Beta-lactamase inhibitor compounds H McGuire, S Bist, N Bifulco, L Zhao, Y Wu, H Huynh, H Xiong, ... US Patent 9,309,245, 2016 | 9 | 2016 |
